Somatic mutations of the protein kinase gene family in human lung cancer.

@article{Davies2005SomaticMO,
  title={Somatic mutations of the protein kinase gene family in human lung cancer.},
  author={Helen R. Davies and C. Travis Hunter and Raffaella Smith and P. Stephens and Chris Greenman and Graham Bignell and J. W. Teague and Adam P. Butler and Sarah J Edkins and Claire E. Stevens and Adrian G. Parker and Sarah O'meara and Tim Avis and Syd Barthorpe and Lisa Brackenbury and Gemma Buck and Jody Clements and Jennifer Cole and Ed M. Dicks and Ken Edwards and Simon Forbes and Matthew John Gorton and Kristian A. Gray and Kelly A. Halliday and Rachel Harrison and Katy Hills and Jonathon Hinton and David Oldham. Jones and Vivienne Kosmidou and Ross Laman and Richard H. Lugg and Andrew Menzies and Janet Elise. Perry and Robert D. Petty and Keiran M Raine and Rebecca Shepherd and Alexandra Joanne Small and Helen M. Solomon and Yvonne Day Stephens and Calli Tofts and Jennifer Varian and Anthony M Webb and Sofie West and Sara Widaa and Andrew Yates and Francis Brasseur and Colin S Cooper and Adrienne M Flanagan and Anthony R Green and Maggie Knowles and Suet Yi Leung and Leendert H. J. Looijenga and Bruce S Malkowicz and Marco Alessandro Pierotti and Bin Tean Teh and Siu Tsan Yuen and Sunil R Lakhani and Douglas F. Easton and Barbara L. Weber and Peter Goldstraw and Andrew G. Nicholson and Richard Wooster and Michael R. Stratton and P. Andrew Futreal},
  journal={Cancer research},
  year={2005},
  volume={65 17},
  pages={
          7591-5
        }
}
Protein kinases are frequently mutated in human cancer and inhibitors of mutant protein kinases have proven to be effective anticancer drugs. We screened the coding sequences of 518 protein kinases (approximately 1.3 Mb of DNA per sample) for somatic mutations in 26 primary lung neoplasms and seven lung cancer cell lines. One hundred eighty-eight somatic mutations were detected in 141 genes. Of these, 35 were synonymous (silent) changes. This result indicates that most of the 188 mutations were… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 236 CITATIONS

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Molecular markers in Finnish lung cancers

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Regulation of cell growth, death, and polarization by ERBB4

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1994
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Similar Papers

Loading similar papers…